Fig. 1.

CEBPA/CSF3R mutant AML demonstrates sensitivity to JAK/STAT and LSD1 inhibition. (A) Mouse bone marrow cells immortalized through retroviral transduction with CSF3R^T618I and CEBPA^V314VW were screened against a panel of 175 inhibitors with established sensitivities in primary patient samples. Drugs with an IC50 < 20% median IC50 of all prior samples are shown. (B) CEBPA/CSF3R mutant AML cells were screened against a panel of epigenetic inhibitors with cytotoxicity assessed after 72 h of culture.